Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CSF1R | P07333 | 5/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093430 | 0.93 | NPC1 (0.58) | NPC1LMNACSF1RNAMPTCYP11B2 | |
| SCHEMBL15093438 | 0.87 | NPC1 (0.56) | NPC1LMNACSF1RNAMPTCYP11B2 | |
| SCHEMBL791888 | 0.81 | NAMPT (0.54) | NPC1LMNANAMPTCYP11B2CYP11B1 | |
| SCHEMBL12978140 | 0.80 | TRPV1 (0.43) | CSF1RHSD17B10 | |
| SCHEMBL789593 | 0.77 | HTT (0.45) | TSHR | |
| SCHEMBL790944 | 0.76 | NAMPT (0.55) | NPC1LMNANAMPTCYP11B2CYP11B1 | |
| SCHEMBL12978154 | 0.75 | NAMPT (0.64) | NPC1LMNANAMPTCYP11B2CYP11B1 | |
| SCHEMBL12978098 | 0.73 | TRPV1 (0.44) | NPC1CSF1RRAB9AHSD17B10 | |
| SCHEMBL790699 | 0.71 | NAMPT (0.73) | NPC1LMNANAMPTCYP11B2CYP11B1 | |
| SCHEMBL1867382 | 0.71 | NPC1 (0.63) | NPC1LMNACSF1RNAMPTCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615917-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012034959-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | CHRM1, CHRM2, GRIN2C | NPC1 2203/4885LMNA 1364/4885CSF1R 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.